by Truveta staff | Feb 26, 2025 | Research
Heart failure with reduced ejection fraction (HFrEF) remains a leading cause of morbidity and mortality. While guideline-directed medical therapy (GDMT) has been shown to improve left ventricular ejection fraction (LVEF), real-world data on LVEF recovery and GDMT...
by Truveta Research | Dec 16, 2024 | Research, Research Insights
In partnership with Reuters, Truveta Research explored the percentage of patients who received a first-time diagnosis of type 2 diabetes, cardiovascular disease, or sleep apnea within 15 days of their first-time GLP-1 prescriptions. Truveta Research found that for...
by Truveta Research | Jul 25, 2024 | Research, Research Insights
The analysis was based on a sample of 17,501,982 patients from January 2018 to May 2024. During the study period, 9,271 patients were tested (using CPT code 93922) for the first time and had a diagnosis of peripheral vascular disease/peripheral artery disease...
by Truveta staff | May 2, 2024 | Research
Leading heart failure researchers have published new research in JACC: Heart Failure. The TREAT-AHF study found that despite significant efforts to improve acute heart failure treatment over the past 20 years, management remains unchanged. Reprieve Cardiovascular is...
by Truveta Research | Mar 6, 2024 | Research, Research Insights
Disparities in time to treatment and treatment outcomes exist for people with severe aortic stenosis receiving TAVR and SAVR procedures. We studied the rate of people who receive TAVR, SAVR, aortic valve repair, and aortic balloon valvuloplasty procedures and time to...
